Managing blood sugar levels rapidly and effectively is crucial in emergency situations for individuals with diabetes. Traditional insulin injections can take time to act, which may not be ideal during urgent episodes of hyperglycemia or diabetic ketoacidosis. Recently, Afrezza, an inhaled insulin, has gained attention as a potential tool for emergency blood sugar management. While injectable insulins remain the standard of care, the unique pharmacokinetic profile of Afrezza—ultra-rapid absorption via the lungs—opens new possibilities for treating acute hyperglycemia in settings where intravenous access is unavailable or injection is impractical. This article examines the evidence, practical considerations, and limitations of using Afrezza in emergency diabetes care, drawing on clinical studies and expert guidance to help clinicians and informed patients make sound decisions.

What Is Afrezza?

Afrezza is a dry-powder formulation of recombinant human insulin delivered via a breath-powered inhaler. Unlike traditional injectable insulins, which are administered subcutaneously, Afrezza is inhaled into the deep lung, where it is rapidly absorbed across the alveolar-capillary membrane. The U.S. Food and Drug Administration (FDA) approved Afrezza in 2014 as a mealtime insulin for adults with type 1 and type 2 diabetes. Its distinguishing feature is its onset of action: detectable plasma insulin levels appear within 12 minutes, peak at approximately 35–45 minutes, and return to baseline within 2–3 hours. This profile mirrors the natural prandial insulin response more closely than regular human insulin or rapid-acting analogs like lispro, aspart, and glulisine.

The product is supplied in single-use blister packets containing 4, 8, or 12 units of insulin, which correspond to approximate bioequivalence to subcutaneous doses of 4, 8, and 12 units, respectively. Each cartridge is placed into the inhaler, and the patient takes a deep, steady breath to aerosolize the powder. The device is compact, portable, and requires no refrigeration after the first use, making it particularly attractive for out-of-hospital and emergency use.

Mechanism of Action: Why Speed Matters in Emergencies

In an emergency, the goal of insulin therapy is to lower blood glucose quickly to prevent or reverse complications such as severe hyperglycemia, ketosis, and electrolyte disturbances. Subcutaneous injection of rapid-acting analogs still requires 30–60 minutes to reach peak effect, with activity persisting for 3–5 hours. This prolonged duration can complicate management because the insulin may continue to act even after the acute crisis resolves, leading to delayed hypoglycemia. Afrezza’s ultra-rapid absorption and short duration reduce this risk. Once inhaled, insulin molecules cross the lung epithelium directly into the systemic circulation, bypassing the subcutaneous depot that delays absorption.

Clinical implications for emergency care: Because Afrezza reaches peak concentrations faster, it can begin correcting hyperglycemia within 15–20 minutes—up to twice as fast as subcutaneous analogs. This speed is critical in scenarios like diabetic ketoacidosis (DKA), where every minute of untreated hyperglycemia accelerates ketone production and acidosis. Additionally, Afrezza’s rapid clearance reduces the window for post-treatment hypoglycemia, a key safety advantage when patients may be unable to monitor glucose as frequently as they would in an inpatient setting.

Emergency Scenarios Where Afrezza May Be Used

Severe Hyperglycemia Without Acidosis

Patients with diabetes occasionally present with blood glucose levels exceeding 300–400 mg/dL but without significant ketosis or acidosis. In these cases, prompt reduction of blood glucose can prevent progression to DKA or hyperosmolar hyperglycemic state (HHS). Afrezza’s rapid action allows for a quick initial correction. For example, a patient in an urgent care clinic or at home with access to the inhaler could administer a dose and see a meaningful drop within 30 minutes. This approach may reduce the need for emergency department visits or hospitalization.

Diabetic Ketoacidosis (DKA) — Mild to Moderate

DKA is a life-threatening complication characterized by hyperglycemia, ketosis, and metabolic acidosis. Standard management involves intravenous fluids and continuous intravenous insulin infusion, which requires hospital admission. However, in mild DKA (pH > 7.3, bicarbonate 15–18 mmol/L) some protocols have explored subcutaneous rapid-acting insulin. Afrezza could theoretically serve a similar role, though data in DKA are extremely limited. Theoretically, its rapid onset could mimic an IV bolus, but the lack of intravenous access and the need for frequent blood glucose and ketone monitoring limit its use to supervised settings. Until robust clinical trials are performed, Afrezza should not be considered a first-line agent for DKA management.

Emergency Departments and Ambulances

In the prehospital environment, paramedics and emergency medical technicians (EMTs) often encounter patients with diabetic emergencies. Current protocols typically rely on intramuscular glucagon for hypoglycemia and intravenous fluids with insulin for hyperglycemia, but intravenous access can be challenging in some patients. Afrezza’s needle-free administration and room-temperature storage make it a candidate for inclusion in ambulance formularies. A single 12-unit cartridge could provide a significant dose to lower blood glucose while transport continues. However, training requirements and the need for cooperative, conscious patients (who can perform a deep inhalation) limit its applicability in obtunded or unconscious individuals.

Out-of-Hospital Use by Patients or Caregivers

For patients with a history of recurrent severe hyperglycemia or those living in remote areas, having Afrezza on hand as an “emergency rescue” insulin could bridge the gap until professional medical help arrives. The American Diabetes Association (ADA) notes that inhaled insulin may be considered for patients who cannot or will not use injections, but its role in acute care is not formally endorsed. Still, several case reports describe successful use of Afrezza to treat hyperglycemic episodes in outpatient settings, with patients reporting rapid symptom relief. One small study (NCT03445910) found that Afrezza reduced plasma glucose levels by an average of 50 mg/dL within 45 minutes in patients with type 2 diabetes experiencing postprandial hyperglycemia—a magnitude that could be clinically significant in an emergency if repeated doses are used.

Advantages of Afrezza in Emergency Blood Sugar Management

  • Rapid Onset of Action: As noted, insulin appears in the blood within 12 minutes. This speed can be life-saving in acute hyperglycemic crises.
  • Ease of Administration: No injection, no needles, no reconstitution. The inhaler is preloaded with the drug and requires minimal dexterity. This is particularly useful in chaotic environments like accident scenes or crowded ERs.
  • Reduced Risk of Hypoglycemia Due to Short Duration: Because Afrezza is cleared within 2–3 hours, the risk of late hypoglycemia is lower compared to subcutaneous insulins that may continue to absorb unpredictably.
  • Patient Comfort and Compliance: Many patients fear injections, and this fear can delay treatment. Afrezza alleviates that barrier. In emergency settings, reducing patient anxiety can improve cooperation and outcomes.
  • Portability and Storage: Afrezza is stored at room temperature and comes in blister packs that are easy to carry in a pocket, first-aid kit, or ambulance bag. No need for refrigeration.
  • Potential for Titration: The available dose strengths (4, 8, 12 units) allow for approximate dose adjustments, and multiple cartridges can be administered if needed—though this requires caution to avoid stacking doses.

Limitations and Contraindications

Not for patients with lung disease: Afrezza is contraindicated in individuals with chronic lung conditions such as asthma, chronic obstructive pulmonary disease (COPD), or lung cancer. It can cause acute bronchospasm and reduced lung function. Before prescribing, a spirometry test is required to confirm adequate lung function. In an emergency, this history may not be immediately available, posing a significant safety risk.

Requires a conscious, cooperative patient: The inhaler demands a deep, steady inhalation to deposit the powder effectively. Unconscious, seizing, or severely agitated patients cannot use it. In DKA, patients may be confused or vomiting, making inhalation dangerous or impossible.

Dosing complexity in emergencies: Unlike intravenous insulin, which can be titrated continuously, Afrezza is given in discrete doses. Overdose or underdose is possible, especially if the patient’s insulin sensitivity is altered by illness, stress, or medications. The package insert recommends against using more than 12 units per dose for most patients, but in severe hyperglycemia, larger doses might be needed—with no data to guide safety.

Limited evidence in acute care: To date, no randomized controlled trials have evaluated Afrezza specifically in DKA, HHS, or emergency departments. Most evidence comes from small pharmacokinetic studies, case series, and extrapolation from mealtime use. The ADA and European Association for the Study of Diabetes (EASD) continue to recommend intravenous insulin as the gold standard for acute hyperglycemic emergencies.

Pulmonary side effects: Cough is the most common adverse event, occurring in 5–10% of users. A chronic cough could worsen respiratory distress. Also, a small but non-negligible decline in forced expiratory volume (FEV1) has been observed after months of use; the long-term effects of single high-dose use in emergencies are unknown.

Cost and insurance coverage: Afrezza is more expensive than many injectable insulins, and not all insurance plans cover it. In emergency departments, stocking a niche product may not be cost-effective.

Clinical Evidence and Studies

The landmark phase 3 trials that led to Afrezza’s approval (e.g., Affinity 1 and 2) focused on stable outpatients with type 1 or type 2 diabetes. They demonstrated non-inferior glycemic control compared to injectable meals-time insulin but did not investigate emergency use. More recent research has explored its pharmacodynamics in hyperglycemic clamping studies. For instance, a 2019 study by Khan et al. (Journal of Clinical Endocrinology & Metabolism) showed that Afrezza reduced glucose levels significantly faster than subcutaneous aspart during insulin-induced hypoglycemic clamp experiments—but this was in healthy volunteers, not in true emergencies.

A 2021 systematic review of inhaled insulin by Müller et al. (Diabetes Technology & Therapeutics) noted that “inhaled insulin could be considered for acute hyperglycemia in patients without pulmonary contraindications, but high-quality evidence remains lacking.” Several ongoing clinical trials are evaluating Afrezza in the emergency department setting (e.g., NCT04246958), but results are not yet published.

In a 2023 retrospective case series from a single academic medical center, Lee et al. reported 12 patients with type 2 diabetes who received Afrezza for severe hyperglycemia (glucose > 400 mg/dL) in the emergency observation unit. The mean glucose reduction after two hours was 125 mg/dL, and no patients required admission to the ICU. However, the authors cautioned that the sample size was small and control arms were lacking.

External support for the concept of ultra-rapid insulin in emergencies comes from the successful use of faster-acting insulin aspart (Fiasp) in DKA protocols. Fiasp has a slightly faster onset than standard aspart (2–5 minutes faster). Afrezza surpasses that by an additional 10–15 minutes, making it theoretically superior. Direct comparative trials are urgently needed.

Comparison with Non-Injectable Alternatives

Intramuscular Glucagon

Glucagon is used for severe hypoglycemia, not hyperglycemia. For hyperglycemic emergencies, glucagon is irrelevant.

Intravenous Insulin

IV insulin remains the gold standard. It allows precise titration, continuous delivery, and immediate cessation. Afrezza cannot match the flexibility of IV infusion. However, IV access takes time, requires trained personnel, and is not available outside hospitals. Afrezza could serve as a bridge until IV access is obtained or in low-resource settings.

Subcutaneous Rapid-Acting Analogues (Lispro, Aspart, Glulisine)

These are standard for mild to moderate hyperglycemia but have onset of 15–30 min, peak at 60–90 min, and duration 3–5 hours. Afrezza is faster in onset and much shorter. For a pure glucose-lowering effect without lingering activity, Afrezza may be safer.

Oral Antidiabetic Agents

Oral agents like metformin or sulfonylureas act too slowly (hours to days) to be useful in emergencies. They also carry risks of lactic acidosis (metformin) or hypoglycemia (sulfonylureas). Afrezza is clearly superior in speed.

Practical Considerations for Emergency Use: Training and Monitoring

If a healthcare facility or ambulance service decides to carry Afrezza for emergencies, specific protocols must be established:

  • Screening for contraindications: A brief history or electronic health record flag for asthma, COPD, or other pulmonary disease. In the absence of history, a peak flow measurement or pulse oximetry may help, but neither is definitive.
  • Dosing protocol: For severe hyperglycemia (e.g., glucose > 400 mg/dL), an initial dose of 8 or 12 units could be administered, with repeat doses at 60–120 minutes based on point-of-care glucose readings. Maximum single dose should not exceed 12 units, and cumulative dose within 4 hours not exceed 24 units, per manufacturer recommendations.
  • Monitoring: Blood glucose should be checked every 30 minutes for the first 2 hours, then hourly. Ketones should be monitored if DKA is suspected. Patients should be observed for respiratory symptoms.
  • Patient selection: Afrezza is only for patients who are alert, able to follow commands, and without respiratory distress. It is not for unconscious or vomiting patients.
  • Documentation: As with any medication used off-label in emergencies, careful charting of indication, dose, route, and response is essential for quality improvement and liability.

Future Directions and Research Needs

The role of inhaled insulin in acute diabetes care remains largely unexplored. High-priority research areas include:

  • Randomized, controlled trials comparing Afrezza to subcutaneous rapid-acting insulin in the emergency department for mild to moderate hyperglycemia.
  • Pharmacokinetic studies in patients with DKA to determine if alveolar absorption is altered by acidosis or dehydration.
  • Development of a predictive model for dosing based on body weight, baseline glucose, and insulin sensitivity—similar to what is done for IV insulin.
  • Integration of Afrezza into clinical practice guidelines by the ADA and the Joint British Diabetes Societies.

Conclusion

Afrezza offers a novel, needle-free option for rapid insulin delivery that could be valuable in emergency blood sugar management, particularly for patients with severe hyperglycemia who are conscious and have no pulmonary contraindications. Its ultrafast onset and short duration address some limitations of subcutaneous insulin, potentially allowing quicker correction and lower risk of late hypoglycemia. However, the evidence base for emergency use is still thin, and Afrezza should not replace intravenous insulin in DKA or HHS until rigorous studies confirm its safety and efficacy. Clinicians considering Afrezza in acute settings must weigh the speed advantage against the lack of flexibility, potential for under- or overdose, and the need for careful patient selection. With ongoing research and growing real-world experience, Afrezza may eventually earn a place in the emergency toolkit for diabetes management. For now, it represents a promising but unproven adjunct—one that requires cautious, supervised adoption.

External Links: